Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

Video

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Ankit Kansagra, MD, assistant professor, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

CAR T-cell therapy has shown unprecedented activity in multiple myeloma, explains Kansagra.

Combining CAR T-cell therapy with other drugs may improve T-cell persistence; however, investigational combinations are still in preclinical stages of research, says Kansagra. CAR T-cell therapy could also show enhanced responses earlier on in treatment. As such, several trials are evaluating CAR T-cell therapy in the early relapse setting rather than in heavily pretreated patient populations.

Furthermore, little is known about the optimal treatment for patients who progress on CAR T-cell therapy. This is an area of unmet need that requires further investigation, concludes Kansagra.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.